Active Ingredient(s): Nateglinide
FDA Approved: * December 22, 2000
Pharm Company: * NOVARTIS
Category: Diabetes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Starlix Overview

Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes. Nateglinide was developed by Ajinomoto, a Japanese company and sold by the Swiss pharmaceutical company Novartis. Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs. Contents 1 Pharmacology 2 Contraindications 3 Comparisons with other drugs for type 2 diabetes 4 Dosage 5 See also 6 References 7 External links Pharmacology Nateglinide lowers blood glucose by stimulating the re...

Read more Starlix Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Starlix Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Tablet: 120mg, 60mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Starlix: (2 results)

Sorted by National Drug Code
  • 0078-0351 Starlix 60 mg Oral Tablet by Novartis Pharmaceuticals Corporation
  • 0078-0352 Starlix 120 mg Oral Tablet by Novartis Pharmaceuticals Corporation

Other drugs which contain Nateglinide or a similar ingredient: (1 result)